Home›Companies›Biotech & Pharma›Seraxis

Seraxis Holdings, Inc.

Develops cell replacement therapy for people with insulin-dependent diabetes.

Updated Nov 9, 2026·Latest SEC filing Sep 24, 2026·Suggest an edit

About Seraxis

Seraxis is a private company based in Germantown, Maryland, incorporated in 2021 in Delaware. It has reported $24,000,011 raised in two offerings on Form D since February 2021. Its chief executive is William Rust.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Sep 7, 2026Sep 24, 2026$10,000,000fully sold1$10.0MDebt, Options, Securities on exerciseRule 506(b)Form D ↗
Jan 29, 2021Feb 23, 2021$14,000,011of $40.0M target5$2.8MEquity, OptionsRule 506(b)Form D ↗
Total, two offerings$24,000,011

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Seraxis's Form D filed Sep 24, 2026.

Jerry Baty
Jerry Baty
Director
Also an executive officer at StitchLock.
William Rust
William Rust
Chief Executive Officer, Founder, Director of Board
Carole Welsch
Carole Welsch
Chief Operating Officer, Co-Founder

Earlier filings also listed Roy Arup (director, last listed Feb 2021), James Topper (director, last listed Feb 2021), Gi-Hyeok Yang (director, last listed Feb 2021) and Bernie Treidl (director, last listed Feb 2021).

Sources

  1. SECSeraxis Holdings, Inc. filing history
  2. CompanySeraxis leadership